Current Edition

Dupixent

On a roll, Sanofi raises Dupixent’s peak sales target to €13B-plus

Over the years, as Sanofi and Regeneron’s Dupixent racked up new indications and approached the French pharma giant’s 10 billion euro peak sales goal, analysts had started …

Continue Reading →
Dupixent

Sanofi and Regeneron’s Dupixent aces another test, this time in the debilitating itch condition prurigo nodularis

Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …

Continue Reading →